Citations

Mayo Clinic

Showing 10 of 108551 citations.

Comparing biological markers of Alzheimer's disease across blood fraction and platforms: Comparing apples to oranges
O’Bryant, Sid E. , Lista, Simone , Zhang, Fan , Hall, James , Lovestone, Simon , Gupta, Veer Bala , Graff‐Radford, Neill, Martins, Ralph N. , Jeromin, Andreas, Kling, Mitchel A. , Hampel, Harald , Area, ISTAART Blood Based Biomarker Professional Interest, Rissman, Robert A. , Edwards, Melissa , Zetterberg, Henrik , Graff‐Radford, Neill, Waring, Stephen C. , Oh, Esther S , Baker, Laura D. , Area, ISTAART Blood Based Biomarker Professional Interest, O'Bryant, Sid

Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring | December 29, 2015 | Volume: 3 | Issue: 1 | Pages: 27-34

10.1016/j.dadm.2015.12.003 | PMID 27019866 Get It

AbstractIntroductionThis study investigated the comparability of potential Alzheimer's disease (AD) biomarkers across blood fractions and assay platforms.MethodsNonfasting serum and plasma samples from 300 participants (150 AD patients and 150 controls) were analyzed. Proteomic markers were obtained via electrochemiluminescence or Luminex technology. Comparisons were conducted via Pearson correlations. The relative importance of proteins within an AD diagnostic profile was examined using random forest importance plots.ResultsOn the Meso Scale Discovery multiplex platform, 10 of the 21 markers shared >50% of the variance across blood fractions (serum amyloid A R2 = 0.99, interleukin (IL)10 R2 = 0.95, fatty acid‐binding protein (FABP) R2 = 0.94, I309 R2 = 0.94, IL‐5 R2 = 0.94, IL‐6 R2 = 0.94, eotaxin3 R2 = 0.91, IL‐18 R2 = 0.87, soluble tumor necrosis factor receptor 1 R2 = 0.85, and pancreatic polypeptide R2 = 0.81). When examining protein concentrations across platforms, only five markers shared >50% of the variance (beta 2 microglobulin R2 = 0.92, IL‐18 R2 = 0.80, factor VII R2 = 0.78, CRP R2 = 0.74, and FABP R2 = 0.70).DiscussionThe current findings highlight the importance of considering blood fractions and assay platforms when searching for AD relevant biomarkers.
Transoral robotic medial hypopharyngectomy: Surgical technique
Sims, John R. , Robinson, Nathaniel L. , Moore, Eric J. , Janus, Jeffrey R.

Head & Neck | December 29, 2015 | Volume: 38 | Issue: S1 | Pages: No page available

10.1002/hed.24360 | PMID 26714289 Get It

AbstractBackgroundTransoral robotic surgery (TORS) has been shown to be both feasible and oncologically sound for use in early T classification hypopharyngeal cancers. The purpose of this study was to present our surgical technique for performing a transoral robotic hypopharyngectomy.MethodsA 48‐year‐old man with a T2, N2a, M0 squamous cell carcinoma of the hypopharynx underwent a transoral robotic hypopharyngectomy and a left select neck dissection of levels II to IV.ResultsThe hypopharyngeal tumor was removed en bloc after circumferential cuts were made until the tumor was finally amputated from the apex of the piriform sinus. Negative margins were achieved. A left select neck dissection was performed. The patient was tolerating an oral diet and his tracheostomy tube was decannulated before discharge.ConclusionTORS offers improved manual dexterity and tumor manipulation over conventional transoral approaches to hypopharyngeal cancers. It is both a feasible and effective method for certain early‐stage hypopharyngeal cancers. © 2015 Wiley Periodicals, Inc. Head Neck 38: E2127–E2129, 2016
Diffuse Alveolar Hemorrhage Secondary to Antineutrophil Cytoplasmic Antibody–Associated Vasculitis: Predictors of Respiratory Failure and Clinical Outcomes
Cartin‐Ceba, Rodrigo , Diaz-Caballero, L.A. , Al‐Qadi, Mazen O. , Τryfon, Stavros , Ytterberg, Steven R. , Fervenza, Fernando C. , Specks, Ulrich

Arthritis & Rheumatology | December 29, 2015 | Volume: 68 | Issue: 6 | Pages: 1467-1476

10.1002/art.39562 | PMID 26713723 Get It

Objective To identify predictors of respiratory failure and to evaluate the therapeutic efficacy of plasma exchange (PE) and of rituximab versus cyclophosphamide in a cohort of patients with diffuse alveolar hemorrhage (DAH) secondary to antineutrophil cytoplasmic antibody–associated vasculitis (AAV) with or without respiratory failure. Methods We performed a single‐center historical cohort study of all consecutive patients with AAV‐associated DAH who were evaluated over a 16‐year period. Logistic regression models were developed to examine the predictive role of the baseline clinical characteristics for the development of respiratory failure, and for the effect of PE and remission induction therapy on the main outcome (complete remission at 6 months). Results Seventy‐three patients with DAH were identified, and 34 of them experienced respiratory failure. The degree of hypoxemia upon initial presentation, a higher percentage of neutrophils in the bronchoalveolar lavage fluid cell count, and higher C‐reactive protein levels were independently associated with the development of respiratory failure. PE was not associated with achieving complete remission at 6 months, with an odds ratio (OR) of 0.49 (95% confidence interval [95% CI] 0.12–1.95) ( P = 0.32). Rituximab treatment was independently associated with achieving complete remission at 6 months (OR 6.45 [95% CI 1.78–29], P = 0.003). Conclusion Our findings indicate that the most important predictor of respiratory failure in patients with DAH secondary to AAV is the degree of hypoxemia upon presentation. No clear benefit of the addition of PE to standard remission induction therapy was demonstrated. Complete remission by 6 months was achieved at a higher rate with rituximab than with cyclophosphamide in patients with DAH secondary to AAV, including those needing mechanical ventilation.
Literature‐based immunization recommendations for patients requiring immunosuppressive medications for autoimmune bullous dermatoses
Laniosz, Valerie, Lehman, Julia S. , Poland, Gregory A., Wetter, David A. , Poland, Gregory A. , Lehman, Julia S

International Journal of Dermatology | December 29, 2015 | Volume: 55 | Issue: 6 | Pages: 599-607

10.1111/ijd.13140 | PMID 26711431 Get It

AbstractAutoimmune bullous diseases, such as pemphigus, pemphigoid, and dermatitis herpetiformis, are uniquely associated with vulnerability in the mucocutaneous barrier against infection. The management of immunobullous diseases is complex and may at times require immunosuppressive medications. Iatrogenic immunosuppression may increase susceptibility to vaccine‐preventable illnesses. Currently, there are no guidelines to assist the clinician treating patients with immunobullous disease regarding the delivery of various vaccinations. The aim of this review is to provide recommendations for immunization in the unique setting of immunobullous disease. Recommendations are based on careful review of the literature in other conditions requiring iatrogenic immunosuppression, as well as the most recent Centers for Disease Control and Prevention guidelines. Immunization with nonlive vaccines appears to be a safe and effective strategy for preventing infection in the particularly susceptible patient with immunobullous disease. Opportunities for live vaccine administration may become available at lower levels of immune suppression or during clinical remission when immunosuppressive regimens can be reduced. Anticipatory vaccination before the initiation of iatrogenic immunosuppression is ideal. Although immunologic response to vaccination may be suboptimal during immunosuppression, nonlive vaccination is strongly recommended for this patient population.
Identification of a novel senolytic agent, navitoclax, targeting the Bcl‐2 family of anti‐apoptotic factors
Zhu, Yi , Tchkonia, Tamar , Fuhrmann‐Stroissnigg, Heike , Dai, Haiming , Ling, Yuanyuan, Pirtskhalava, Tamar , Giorgadze, Nino, Johnson, Kurt O. , Giles, Cory B. , Wren, Jonathan D. , Niedernhofer, Laura J. , Robbins, Paul D. , Kirkland, James L. , Tchkonia, Tamara, Stout, Michael B, Stout, Michael B , Tchkonia, T , Niedernhofer, Laura J , Robbins, Paul D , Zhu, Yi , Dai, Haiming

Aging Cell | December 29, 2015 | Volume: 15 | Issue: 3 | Pages: 428-435

10.1111/acel.12445 | PMID 26711051 Get It

Cancer Survivorship Care: An Opportunity to Revisit Cancer Genetics
Ruddy, Kathryn J. , Risendal, Betsy , Garber, Judy E. , Partridge, Ann H.

Journal of Clinical Oncology | December 29, 2015 | Volume: 34 | Issue: 6 | Pages: 539-541

10.1200/jco.2015.63.5375 | PMID 26712228 Get It

Antibiofilm Activity of Electrical Current in a Catheter Model
Voegele, Paul, Badiola, Jon , Schmidt-Malan, Suzannah M., Karau, Melissa J. , Greenwood‐Quaintance, Kerryl E. , Mandrekar, Jayawant N. , Patel, Robin , Patel, Robin

Antimicrobial Agents and Chemotherapy | December 29, 2015 | Volume: 60 | Issue: 3 | Pages: 1476-1480

10.1128/aac.01628-15 | PMID 26711752 Get It

ABSTRACT Catheter-associated infections are difficult to treat with available antimicrobial agents because of their biofilm etiology. We examined the effect of low-amperage direct electrical current (DC) exposure on established bacterial and fungal biofilms in a novel experimental in vitro catheter model. Staphylococcus epidermidis , Staphylococcus aureus , Escherichia coli , Pseudomonas aeruginosa , and Candida parapsilosis biofilms were grown on the inside surfaces of polyvinyl chloride (PVC) catheters, after which 0, 100, 200, or 500 μA of DC was delivered via intraluminally placed platinum electrodes. Catheter biofilms and intraluminal fluid were quantitatively cultured after 24 h and 4 days of DC exposure. Time- and dose-dependent biofilm killing was observed with all amperages and durations of DC administration. Twenty-four hours of 500 μA of DC sterilized the intraluminal fluid for all bacterial species studied; no viable bacteria were detected after treatment of S. epidermidis and S. aureus biofilms with 500 μA of DC for 4 days.
Immunovirotherapy with vesicular stomatitis virus and PD-L1 blockade enhances therapeutic outcome in murine acute myeloid leukemia
Shen, Weiwei , Patnaik, Mrinal M. , Ruiz, Autumn, Russell, Stephen J. , Peng, Kah-Whye , Schulze, Autumn J. , Russell, Stephen J

Blood | December 28, 2015 | Volume: 127 | Issue: 11 | Pages: 1449-1458

10.1182/blood-2015-06-652503 | PMID 26712908 Get It

Key Points IV therapy with oncolytic VSV-IFNβ-NIS virus extends survival of immunocompetent mice with AML. The therapeutic outcome of VSV-IFNβ-NIS–treated mice with AML is augmented by anti-PD-L1 immunotherapy.
Impaired Flow-Mediated Dilation Before, During, and After Preeclampsia
Weissgerber, Tracey L. , Milić, Nataša , Milin‐Lazović, Jelena , Milin-Lazovic, Jelena S, Garovic, Vesna D. , Weissgerber, Tracey L , Milic, N

Hypertension | December 28, 2015 | Volume: 67 | Issue: 2 | Pages: 415-423

10.1161/hypertensionaha.115.06554 | PMID 26711737 Get It

Endothelial dysfunction is believed to play a critical role in preeclampsia; however, it is unclear whether this dysfunction precedes the pregnancy or is caused by pathophysiological events in early pregnancy. It is also unclear for how long vascular dysfunction may persist postpartum and whether it represents a mechanism linking preeclampsia with future cardiovascular disease. Our objective was to determine whether women with preeclampsia had worse vascular function compared with women who did not have preeclampsia by performing a systematic review and meta-analysis of studies that examined endothelial dysfunction using flow-mediated dilation. We included studies published before May 29, 2015, that examined flow-mediated dilation before, during, or after preeclampsia. Differences in flow-mediated dilation between study groups were evaluated by standardized mean differences. Out of 610 abstracts identified through PubMED, EMBASE, and Web of Science, 37 studies were eligible for the meta-analysis. When compared with women who did not have preeclampsia, women who had preeclampsia had lower flow-mediated dilation before the development of preeclampsia (≈20–29 weeks gestation), at the time of preeclampsia, and for 3 years postpartum, with the estimated magnitude of the effect ranging between 0.5 and 3 standard deviations. Similar effects were observed when the analysis was limited to studies that excluded women with chronic hypertension, smokers, or both. Vascular dysfunction predates preeclampsia and may contribute to its pathogenesis. Future studies should address whether vascular changes that persist after preeclamptic pregnancies may represent a mechanistic link with increased risk for future cardiovascular disease.
Midterm Outcomes of Reverse (Anteverting) Periacetabular Osteotomy in Patients With Hip Impingement Secondary to Acetabular Retroversion
Parry, Joshua A. , Swann, R. Presley, Trousdale, Robert T. , Swann, Russell P, Erickson, Jill A. , Peters, Christopher L. , Sierra, Rafael J.

The American Journal of Sports Medicine | December 28, 2015 | Volume: 44 | Issue: 3 | Pages: 672-676

10.1177/0363546515620382 | PMID 26712890 Get It

Background: There is a paucity of data on the results of reverse (anteverting) periacetabular osteotomy (RPAO) for treatment of femoroacetabular impingement (FAI) secondary to acetabular retroversion. Purpose: To evaluate the midterm outcomes of RPAO for FAI secondary to acetabular retroversion in those with and without hip dysplasia. Study Design: Cohort study; Level of evidence, 3. Methods: A retrospective review identified RPAOs performed on patients with acetabular retroversion in isolation or in the setting of dysplasia (lateral center-edge angle [LCEA] ≤19°). Acetabular retroversion with FAI was diagnosed clinically and radiographically, with a positive crossover and posterior wall signs on pelvic radiographs. Twenty-three patients (30 hips) met the inclusion criteria; 20 hips with isolated retroversion and 10 hips with retroversion and hip dysplasia. The average age at the time of the procedure was 26 years (range, 13-45 years). The average length of follow-up was 5 years (range, 2-19 years). Harris Hip Score (HHS) and radiographs were evaluated preoperatively and at last follow-up. Results: The mean preoperative LCEA was 31° (range, 22°-49°) in the isolated retroversion group and 9° (range, –4° to 17°) in the dysplastic group. Postoperatively, the LCEA in the dysplastic group increased to 35° (range, 15°-46°) ( P = .0001). The crossover sign corrected in 55% (11/20) of the isolated retroversion group and 80% (8/10) of the dysplastic group. The acetabular index (mean ± SD) improved from 1.3 ± 0.3 to 1.7 ± 0.6 ( P = .0001), indicating improved anteversion. At the latest follow-up, the average HHS in the isolated retroversion group increased from 58 preoperatively (range, 23-77) to 93 (range, 68-100) ( P = .0001); the HHS in the dysplastic group improved from 49 (range, 20-74) to 92 (range, 77-100) ( P < .0001). Complication rates were similar in both groups. Excluding hardware removal, additional surgeries were performed in 13% (4/30). Conclusion: RPAO performed for FAI in the young patient with isolated acetabular retroversion or retroversion in the setting of dysplasia successfully improved clinical and radiographic results at mid- to long-term follow-up.